Can I switch from Wegovy to Zepbound?

Switching from Wegovy to Zepbound is increasingly common in 2026. Reasons include: Wegovy intolerance (severe GI side effects), weight loss plateau, or insurance coverage loss for Wegovy. Wait one week after final Wegovy dose, then start Zepbound at 2.5mg starter and titrate over 4-week intervals. SURMOUNT-1 trial showed Zepbound delivers ~22% body weight loss vs Wegovy ~15% in SELECT. The OSA-with-obesity FDA indication (December 2024) made Zepbound easier to approve on plans that previously denied weight-loss tirzepatide. LillyDirect cash-pay at $449/month is a backup if insurance denies.

Is Zepbound better than Wegovy for weight loss?

For pure weight loss, Zepbound (tirzepatide) is statistically superior to Wegovy (semaglutide). SURMOUNT-1 showed ~22% body weight reduction on Zepbound 15mg vs SELECT trial ~15% on Wegovy 2.4mg. The molecules differ — tirzepatide acts on both GLP-1 and GIP receptors, while semaglutide is GLP-1 only. For cardiovascular outcomes, Wegovy has the longer track record — the SELECT trial demonstrated mortality benefit over 5 years. SURPASS-CVOT data for tirzepatide is still maturing. Cash-pay pricing is in the same ballpark ($449/mo via LillyDirect vs $349/mo via NovoCare). Insurance coverage typically favors Wegovy for weight loss and Zepbound when OSA-with-obesity indication applies.

Hitting a plateau: months 8-12 (2026) — what to expect on a GLP-1

What happens

What actually happens

Weight loss stalls at the dose that previously drove loss. Hunger may slightly increase. Resting metabolic rate has dropped as expected with significant weight loss.

What to watch

Red flags and adjustments

Are you actually under-dosed (still at 1.7 mg Wegovy when 2.4 mg is the trial-maintenance dose)? Did you change food intake unconsciously? Is body composition still improving (smaller waist) even if scale is flat?

Evidence

What trials show

Adaptive thermogenesis: keeping off 10% or more of body weight comes with an approximate 20-25% drop in 24-hour energy expenditure — mostly from non-resting expenditure, not resting metabolic rate. This is biology, not failure. Plateaus are expected; they are not the drug failing.

Editorial verdict

Plateau ≠ failure. First check: are you at the trial-maintenance dose? Second: track protein intake (often quietly drops). Third: switch to Zepbound if on Wegovy maximum dose. Do not stop the drug as the first move.